Stockscreener 앱 받기
132.66
0.98%
1.29
시간 외 거래:
132.66
전일 마감가:
$131.37
열려 있는:
$132.015
하루 거래량:
4.43M
Relative Volume:
0.71
시가총액:
$230.89B
수익:
$43.11B
순이익/손실:
$13.94B
주가수익비율:
16.62
EPS:
7.98
순현금흐름:
$6.78B
1주 성능:
+0.05%
1개월 성능:
+3.63%
6개월 성능:
-2.36%
1년 성능:
+17.65%
1일 변동 폭
$131.17
$132.84
1주일 범위
$130.14
$132.96
52주 변동 폭
$110.86
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.66 | 228.64B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.50 | 156.70B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
391.41 | 148.97B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.81 | 117.96B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
81.34 | 47.69B | 5.69B | 1.41B | 577.90M | 6.95 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Price action breakdown for Abbott Laboratories2025 Year in Review & Free Expert Verified Stock Movement Alerts - Newser
Stock Analysis | Abbott Laboratories OutlookNavigating Mixed Signals in a Volatile Market - AInvest
IoT in Healthcare Market to See Thriving Worldwide | Abbott Laboratories, Philips, Medtronic - openPR.com
Ranking Abbott Laboratories among high performing stocks via toolsJuly 2025 Momentum & Community Consensus Picks - Newser
Does Abbott Laboratories fit your quant trading model2025 Winners & Losers & Low Risk Investment Opportunities - Newser
St. Jude Medical delivers sales growth for Abbott Labs - Star Tribune
Abbott Laboratories: Is The Growth in Continuous Glucose Monitoring (CGM) & Ketone Monitoring Here To Stay? - Smartkarma
What MACD and RSI say about Abbott Laboratories2025 Trading Recap & Daily Entry Point Trade Alerts - Newser
Abbott Laboratories stock trend outlook and recovery path2025 Year in Review & Momentum Based Trading Ideas - Newser
Applying chart zones and confluence areas to Abbott Laboratories2025 Institutional Moves & Weekly High Potential Alerts - Newser
Live market analysis of Abbott Laboratories2025 Price Action Summary & Comprehensive Market Scan Insights - Newser
Is now a turning point for Abbott Laboratories2025 Price Action Summary & Step-by-Step Trade Execution Guides - Newser
How to integrate Abbott Laboratories into portfolio analysis toolsJuly 2025 PreEarnings & Fast Gaining Stock Reports - Newser
Abbott Laboratories Severance Pay: Your Rights Explained - Samfiru Tumarkin LLP
Abbott receives expanded approval for Navitor TAVR system - Cardiovascular Business
Is Abbott Laboratories stock poised for growthBuy Signal & Consistent Return Investment Signals - Newser
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now? - TradingView
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott gets EU CE Mark for expanded use of Navitor TAVI system - Seeking Alpha
Abbott Laboratories Receives CE Mark for Expanded Indication for Navitor Aortic Valve Implant - MarketScreener
Major Breakthrough: Abbott's Navitor Heart Valve Now Approved for All Surgical Risk Levels in Europe - Stock Titan
Abbott Laboratories stock chart pattern explained2025 Big Picture & Low Risk Entry Point Tips - Newser
What makes Abbott Laboratories stock price move sharplyJuly 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Formula makers have been hiding the truth — and endangering the tiniest babies | Opinion - The Tennessean
Price momentum metrics for Abbott Laboratories explainedWeekly Profit Recap & Fast Entry Momentum Trade Alerts - Newser
Can machine learning forecast Abbott Laboratories recoveryJuly 2025 Trends & Community Verified Trade Signals - Newser
Abbott wins expanded CE mark for Navitor TAVI system, reports updated TEER guidelines - MassDevice
Tools to assess Abbott Laboratories’s risk profileMarket Growth Summary & Real-Time Sentiment Analysis - Newser
The top Abbott stories of 2025 so far - MassDevice
What institutional flow reveals about Abbott LaboratoriesStop Loss & Momentum Based Trading Signals - Newser
Genetic Material Market Size, Trends and Top Companies (2025 – 2034 Forecast Period) - GlobeNewswire Inc.
Abbott Laboratories CEO warns tariffs are here to stay, points to new US investments [Video] - AOL.com
Abbott Laboratories half-year profit soars over 65% - Mettis Global
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
0.45%
자본화:
|
볼륨(24시간):